Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: Systemic and local immune responses

Journal of Infectious Diseases

Volumn 162, Issue 6, 1990, Pages 1291-1297

  Faden, Howard ^a,b   Modlin, John F ^a,b   Thoms, Mary Lou ^a,b   McBean, A Marshall ^a,b   Ferdon, Mary Beth ^a,b   Ogra, Pearay L ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPLOID CELL VACCINE; IMMUNOGLOBULIN A; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; FEMALE; HUMAN; INFANT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, VIRAL; COMPARATIVE STUDY; FECES; FEMALE; HUMAN; IMMUNOGLOBULIN A; INFANT; MALE; NEUTRALIZATION TESTS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; POLIOVIRUSES; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025203093     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/162.6.1291     Document Type: Article

References (30)

1. Schonberger LB, Kaplan J, Kim-Farley R, Moore M, Eddins DL, Hatch M. Control of paralytic poliomyelitis in the United States. Rev Infect Dis 1984;6(suppl):S434–S426
2. Kim-Farley RJ, Bart KJ, Schonberger LB, Orenstein WA, Nkowane BM, Hinman AR, Kew OM, Hatch MH, Kaplan JE. Poliomyelitis in the USA: virtual elimination of disease caused by wild virus. Lancet 1984;2:1315–1317
3. Centers for Disease Control. Poliomyelitis surveillance summary 1980-1981. Atlanta: CDC, 1982
4. Ghendon YZ, Sanakoyeva LI. Comparison of the resistance of the internal tract to poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virol (Praha) 1961;5:265–273
5. Henry JL, Jaikaran ES, Davies JR, Tomlinson AJH, Mason PJ, Barnes JM, Beale AJ. A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Camb) 1966;64:105–120
6. Nkowane BM, Wassilak GF, Orenstein WA, Bart KJ, Schonberger LB, Hinman AR, Kew OM. Vaccine-associated paralytic poliomyelitis, United States: 1973 through 1984. JAMA 1987;257:1335–1340
7. van Wezel AL, van Steenis G, Hannik CA, Cohen H. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev Biol Stand 1978;41:159–168
8. Simoes EAF, Padmini B, Steinhoff MC, Jadhav M, John TJ. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child 1985;139:977–980
9. Grenier B, Hamza B, Biron G, Xueref C, Viarme F, Roumiantzeff M. Seroimmunity following vaccination in infants by an inactivated poliovirus vaccine prepared on Vero cells. Rev Infect Dis 1984;6(suppl):S545–S547
10. McBean AM, Thorns ML, Johnson RH, Gadless BR, MacDonald B, Nerhood L, Cummins P, Hughes J, Kinnear J, Watts C, Kraft M, Albrecht P, Boone EJ, Moore M, Frank JA Jr, Bernier R. A comparison of the serologic responses to oral and injectable trivalent poliovirus vaccines. Rev Infect Dis 1984;6(suppl):S552-S555
11. Marwick C. Vaccine policy likely to be reassessed in 1990s when polio-DTP combination becomes available. JAMA 1988;259:3523–3524
12. McBean AM, Modlin JF. Rationale for the sequential use of inactivated poliovirus vaccine and live attenuated poliovirus vaccine for routine poliomyelitis immunization in the United States. Pediatr Infect Dis J 1987;6:881–887
13. Albrecht P, van Steenis G, van Wezel AL, Salk J. Standardization of poliovirus neutralizing antibody tests. Rev Infect Dis 1984;6(suppl):S540-S544
14. Lim KA, Benyesh-Melnick M. Typing of viruses by combinations of antiserum pools: application to typing of enteroviruses. J Immunol 1960;84:309–317
15. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. NewYork: John Wiley & Sons, 1981
16. Robertson SE, Drucker JA, Fabre-Teste B, N'Diaye M, Traverso HP, Rovira EZ, Sow A, Sy MTA, Diouf F. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988;1:897–899
17. Batson R, Christine A, Mazur B, Barrick JH. Response of the young infant to poliomyelitis vaccine given separately and combined with other antigens. Pediatrics 1958;21:1–7
18. Lepow ML, Warren RJ, Gray N, Ingram VG, Robbins FC. Effect of Sabin type 1 poliomyelitis vaccine administered by mouth to newborn infants. N Engl J Med 1961;264:1071–1078
19. Glezen WP, Lamb GA, Belden EA, Chin TD. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol 1966;83:224–237
20. Nishio O, Ishihara Y, Sakae K, Nonomura Y, Kuno A, Yasukawa S, Inoue H, Miyamura K, Kono R. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. J Biol Stand 1984;12:1–10
21. Bodian D, Nathanson N. Inhibitory effects of passive antibody on virulent poliovirus excretion and on immune response in chimpanzees. Bull Johns Hopkins Hosp 1960;107:143–162
22. Selvakumar R, John TJ. Intestinal immunity induced by inactivated poliovirus vaccine. Vaccine 1987;5:141–144
23. Onorato I, Modlin J, Bernier R, McBean M, Thoms ML. Intestinal immunity induced by enhanced potency IPV and OPV [abstract 494]. In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York). Washington, DC: American Society for Microbiology, 1987
24. Brown GC. Duration of immunity. In: Poliomyelitis: 5th International Poliomyelitis Conference (Copenhagen). Philadelphia: J. B. Lippincott, 1961:146–154
25. Swartz TA, Ben-Porath E, Kanaaneh H, Leitner L, Goldblum N. Comparison of inactivated poliovirus vaccine and oral poliovirus vaccine programs in Israel. Rev Infect Dis 1984;6(suppl):S556–S561
26. von Magnus H, Peterson I. Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 1984;6(suppl):S471–S474
27. Update: poliomyelitis outbreak-Finland, 1984-1985. MMWR 1986;35:82-86
28. Hovi T, Huovilainen A, Kuronen T. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet 1986;1:1427–1432
29. Roivainen M, Hovi T. Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine. J Virol 1987;61:3749–3753
30. Zhaori G, Sun M, Faden HS, Ogra P. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J Infect Dis 1989;159:1018–1024